Liminatus Pharma, Inc. Class A Common Stock (LIMN) Institutional Ownership

Based on Q1 2026 13F filings, institutional ownership of Liminatus Pharma, Inc. Class A Common Stock stands at 5.7%, held across 15 reporting institutions.

CITADEL ADVISORS LLC is the largest reported institutional holder of LIMN, with approximately 677,518 shares worth $0.00B as of Q1 2026.

Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of LIMN, including CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, TWO SIGMA SECURITIES, LLC.

Our composite Smart Money Score for LIMN is 66 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

6 institutions opened new positions in LIMN during Q1 2026, while 3 fully exited. 2 added to existing positions and 7 trimmed.

LIMN institutional ownership fell by 0.14 percentage points quarter-over-quarter, with a net change of +3 holders.

The top 10 institutions account for 98.7% of all reported 13F value in LIMN, and the top 25 account for 100.0%.

All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.